Efficacy of medroxyprogesterone acetate treatment and retreatment for atypical endometrial hyperplasia and endometrial cancer

2017 ◽  
Vol 44 (1) ◽  
pp. 151-156 ◽  
Author(s):  
Satoshi Tamauchi ◽  
Hiroaki Kajiyama ◽  
Fumi Utsumi ◽  
Shiro Suzuki ◽  
Kaoru Niimi ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Medroxyprogesterone Acetate ◽  
Endometrial Hyperplasia ◽  
Atypical Endometrial Hyperplasia

Administration of Cabergoline Contributes to Preserving Fertility in Young Hyperprolactinemic Patients With Endometrial Cancer Treated With Medroxyprogesterone Acetate

2018 ◽  
Vol 28 (3) ◽  
pp. 539-544 ◽  
Author(s):  
Chimeddulam Erdenebaatar ◽  
Munekage Yamaguchi ◽  
Fumitaka Saito ◽  
Mahina Monsur ◽  
Ritsuo Honda ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Medroxyprogesterone Acetate ◽  
Endometrial Hyperplasia ◽  
Early Stage ◽  
University Hospital ◽  
Serum Prolactin ◽  
Atypical Endometrial Hyperplasia ◽  
Kaplan Meier ◽  
Preservation Of Fertility ◽  
The Mean

BackgroundAn association between high levels of serum prolactin and endometrial cancer (EC) has been reported. However, the effect of antiprolactin drugs on hyperprolactinemic patients with EC has not been determined. The aim of this study was to confirm the effect of cabergoline on young hyperprolactinemic patients treated with medroxyprogesterone acetate (MPA) for the preservation of fertility.MethodsA retrospective observational study was conducted to identify patients with atypical endometrial hyperplasia or early-stage EC aged 40 years or younger who were treated with oral MPA in Kumamoto University Hospital between 1998 and 2016.ResultsThirty-four patients were identified and divided into two groups of 17 patients each, including a nonadministration of cabergoline group (noncabergoline group) and an administration of cabergoline group (cabergoline group). The ratio of pathological diagnoses of EC in the noncabergoline group was significantly lower than that in the cabergoline group (29.4% vs 70.6%, P = 0.016). The mean serum prolactin levels showed a significant decrease after the administration of cabergoline in the cabergoline group (25.2 [24.0] vs 5.2 [4.2] ng/mL, P = 0.003), and this decreased level was also significantly lower than that in the noncabergoline group (5.2 [4.2] vs 12.0 [5.0] ng/mL, P < 0.001). Kaplan-Meier analysis conducted for 150 months revealed that the estimated mean period until hysterectomy in the noncabergoline group was significantly shorter than that in the cabergoline group (83.5 vs 140.8 months, P = 0.007). Significant differences were observed in EC but not atypical endometrial hyperplasia based on histological classification (25.6 vs 138.0 months, P = 0.001).ConclusionsThe administration of cabergoline may contribute to preserving fertility in young hyperprolactinemic patients with EC who were treated with MPA.

New Variant Of Hormonal Treatment For Atypical Endometrial Hyperplasia And An Early Endometrial Cancer With Fertility Preservation

2019 ◽  
pp. 36-45
Author(s):  
Olga V. Novikova ◽  
Cholpon A. Avasova ◽  
Elena G. Novikova ◽  
Ksenia V. Krasnopolskaya ◽  
Yulia A. Lozovaya ◽  
...  
Keyword(s):  
Endometrial Cancer ◽  
Fertility Preservation ◽  
Endometrial Hyperplasia ◽  
Hormonal Treatment ◽  
Atypical Endometrial Hyperplasia ◽  
New Variant
Sign in / Sign up

Export Citation Format

Share Document